Hutchmed/$HCM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Hutchmed
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.
Ticker
$HCM
Sector
Primary listing
Industry
Pharmaceuticals
Headquarters
Hong Kong, Hong Kong
Employees
1,811
ISIN
US44842L1035
Website
Hutchmed Metrics
BasicAdvanced
$2.7B
392.76
$0.04
0.75
-
Price and volume
Market cap
$2.7B
Beta
0.75
52-week high
$18.00
52-week low
$11.51
Average daily volume
83K
Financial strength
Current ratio
2.832
Quick ratio
2.677
Long term debt to equity
8.23
Total debt to equity
11.637
Interest coverage (TTM)
-15.22%
Profitability
EBITDA (TTM)
-31.364
Gross margin (TTM)
10.98%
Net profit margin (TTM)
5.99%
Operating margin (TTM)
-6.94%
Effective tax rate (TTM)
15.85%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-2.14%
Return on equity (TTM)
5.04%
Valuation
Price to earnings (TTM)
392.76
Price to revenue (TTM)
21.323
Price to book
2.65
Price to tangible book (TTM)
2.67
Price to free cash flow (TTM)
-770.703
Free cash flow yield (TTM)
-0.13%
Free cash flow per share (TTM)
-2.04%
Growth
Revenue change (TTM)
-24.80%
Earnings per share change (TTM)
-66.28%
3-year revenue growth (CAGR)
20.96%
10-year revenue growth (CAGR)
21.85%
3-year earnings per share growth (CAGR)
-45.71%
10-year earnings per share growth (CAGR)
-4.35%
Bulls say / Bears say
HUTCHMED's divestment of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million allows the company to focus on its core oncology and immunology businesses, potentially enhancing long-term growth. (bnnbloomberg.ca)
The successful U.S. launch of FRUZAQLA™ (fruquintinib) and its subsequent approval in multiple regions, including the EU, positions HUTCHMED as a competitive player in the global oncology market. (markets.businessinsider.com)
HUTCHMED's 2023 revenue surged by 97% to $838 million, driven by strong commercial progress and strategic partnerships, indicating robust financial health and growth potential. (markets.businessinsider.com)
Analysts have downgraded HUTCHMED's stock rating from 'buy' to 'hold', reflecting concerns over future growth prospects and market performance. (defenseworld.net)
Despite recent successes, HUTCHMED's stock experienced a 25% decline, suggesting investor apprehension about the company's valuation and earnings sustainability. (simplywall.st)
The company's high price-to-earnings ratio of 56.2x, compared to the UK market average, may indicate overvaluation and potential for stock price correction. (simplywall.st)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Hutchmed News
AllArticlesVideos
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
GlobeNewsWire·2 weeks ago
HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting
GlobeNewsWire·3 weeks ago
HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Hutchmed stock?
Hutchmed (HCM) has a market cap of $2.7B as of June 19, 2025.
What is the P/E ratio for Hutchmed stock?
The price to earnings (P/E) ratio for Hutchmed (HCM) stock is 392.76 as of June 19, 2025.
Does Hutchmed stock pay dividends?
No, Hutchmed (HCM) stock does not pay dividends to its shareholders as of June 19, 2025.
When is the next Hutchmed dividend payment date?
Hutchmed (HCM) stock does not pay dividends to its shareholders.
What is the beta indicator for Hutchmed?
Hutchmed (HCM) has a beta rating of 0.75. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.